drug · small molecule
Anti-inflammatory
pre_registrationupdated 3mo agoby AimMax Therapeutics Inc🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 11 investigational indications.
targets
Mitogen-activated protein kinase 11Mitogen-activated protein kinase 14
all catalysts(0)
nothing on the calendar yet
Trials studying Anti-inflammatory
- phase1Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
- phase2Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.
- N/AEffect of a Combined Exercise and Anti-Inflammatory Nutritional Intervention in Frail Older Adults
- N/ALong Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)
- N/AAnti-Inflammatory Dietary Intervention for Rheumatoid Arthritis
News(10)
- Kolon TissueGene cuts 37 US staffers after Phase 3 failFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 13h ago
- Regeneron ends eye disease study due to antibody's safety profileThe discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…biospace · 1d ago
- Regeneron ends eye disease study due to antibody's safety profileThe discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…biospace · 1d ago
- Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 programArpeggio Biosciences’ eight-year song has come to an end, as the transcriptome biotech’s CEO admitted the that company’s Nrf2 program had begun to “unravel.”fiercebiotech · 9d ago
- BioVie shares halve on murky Parkinson’s disease readoutBioVie’s stock fell by nearly 50% as the biotech claimed victory in a mid-stage Parkinson’s disease trial using an alternative endpoint to the primary clinical goal.biospace · 13d ago
- Novo Nordisk rocked by late-stage cardiovascular drug failureAn anti-inflammatory drug from Novo Nordisk unexpectedly failed in a Phase 3 study that aimed to prove a link between cardiovascular inflammation and heart disease, the Danish company revealed Frid…endpoints · 19d ago
- STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease studyA Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent cardiovascular complications.stat · 19d ago
- ‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a whileBiogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.fiercebiotech · 21d ago
- Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsNovartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma's second quarter earnings call—though major pickups aren’t completely o…biospace · 29d ago
- Cassidy grills Trump nominee on past vaccine comments in heated exchangeSean Kaufman, Trump's pick for a key pandemic preparedness role, has questioned vaccines and criticized the CDC.stat · 1mo ago
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that